Prospective study of genital human papillomaviruses and nonmelanoma skin cancer

Genital high‐risk human papillomaviruses (HPVs) cause cervical cancer and are also found in a small proportion of nonmelanoma skin cancers (NMSCs). We used cancer registry linkages to follow the 856,000 serum donors included in the Southern Sweden Microbiology Biobank or the Janus Biobank in Norway, for incident skin cancers occurring up to 30 years after serum donation. Serum samples taken before diagnosis of squamous cell carcinoma (SCC) (N = 633), basal cell carcinoma (BCC) (N = 1990) or other NMSC (N = 153) and matched samples from control donors were tested for antibodies to the genital HPV types 16 and 18. Both HPV 16 and 18 were associated with increased risk for SCC [odds ratio (OR) 1.6, 95% confidence interval (CI) 1.1–2.6 and OR 1.7, 95% CI 1.1–2.5, respectively] and other NMSC (OR 2.3, 95% CI 1.0–5.2 and OR 3.5, 95% CI 1.4–8.7, respectively), but not for BCC. Tumor blocks from HPV16 or 18 seropositive cases were tested with real‐time polymerase chain reaction for presence of HPV16 or 18 DNA. No HPV18 DNA was found and only four of 79 SCC cases (two of which were from the perineum/perianal area), one of 221 BCC cases and zero of five cases with other NMSC contained HPV16 DNA. In conclusion, we found prospective evidence that HPV16 and 18 antibodies associate with SCC and other NMSC risk, but not with BCC risk. As only a small proportion of seropositive subjects had evidence of the corresponding HPV DNA in the tumor, most of this excess risk is likely to be due to confounders associated with genital HPV infection.

[1]  J. Dillner,et al.  Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. , 2012, American journal of epidemiology.

[2]  F. Wiklund,et al.  Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[3]  M. Pawlita,et al.  Seropositivity for human papillomavirus and incidence of subsequent squamous cell and basal cell carcinomas of the skin in patients with a previous nonmelanoma skin cancer , 2011, The British journal of dermatology.

[4]  H. Kitasato,et al.  A case of epidermodysplasia verruciformis (EV) with human papillomavirus 16 (HPV16) DNA detected in the skin lesions: can HPV16 infect patients with EV? , 2011, International journal of dermatology.

[5]  M. Kloor,et al.  High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients , 2011, British Journal of Cancer.

[6]  S. Sano,et al.  High prevalence of coinfection with mucosal high-risk type HPV (HR-HPV) and cutaneous HR-HPV in Bowen's disease in the fingers. , 2010, Journal of dermatological science.

[7]  M. Pawlita,et al.  A case‐control study of cutaneous squamous cell carcinoma among Caucasian organ transplant recipients: The role of antibodies against human papillomavirus and other risk factors , 2009, International journal of cancer.

[8]  F. Aubin,et al.  Detection of alpha‐ and beta‐human papillomavirus (HPV) in cutaneous melanoma: a matched and controlled study using specific multiplex PCR combined with DNA microarray primer extension , 2009, Experimental dermatology.

[9]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[10]  X. Castellsagué,et al.  An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. , 2008, Vaccine.

[11]  N. Kiviat,et al.  Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. , 2008, The Journal of investigative dermatology.

[12]  A. Fiander,et al.  Will vaccination against human papillomavirus prevent eye disease? A review of the evidence , 2008, British Journal of Ophthalmology.

[13]  J. Dillner,et al.  Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions , 2008, Cancer Epidemiology Biomarkers & Prevention.

[14]  T. Key,et al.  A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition , 2007, International journal of cancer.

[15]  J. Dillner,et al.  Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. , 2007, The Journal of infectious diseases.

[16]  S. Franceschi,et al.  Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea , 2007, Cancer Epidemiology Biomarkers & Prevention.

[17]  M. Pawlita,et al.  Suppression of non-specific binding in serological Luminex assays. , 2006, Journal of immunological methods.

[18]  J. Singh.  Clinical Trial Results , 2006 .

[19]  Markus F Templin,et al.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. , 2005, Clinical chemistry.

[20]  F. Bonvicini,et al.  Presence of high‐risk mucosal human papillomavirus genotypes in primary melanoma and in acquired dysplastic melanocytic naevi , 2005, The British journal of dermatology.

[21]  Claude Fauquet,et al.  Classification of papillomaviruses. , 2004, Virology.

[22]  W. Sterry,et al.  Human Papillomavirus and Overexpression of P16INK4a in Nonmelanoma Skin Cancer , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[23]  C. Garbe,et al.  The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. , 2003, Cancer research.

[24]  U. Gyllensten,et al.  Real-Time PCR-Based System for Simultaneous Quantification of Human Papillomavirus Types Associated with High Risk of Cervical Cancer , 2003, Journal of Clinical Microbiology.

[25]  B. Hansson,et al.  Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. , 2003, The Journal of general virology.

[26]  R. Westendorp,et al.  Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. , 2003, Cancer research.

[27]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[28]  M. Lehtinen,et al.  Understanding racial-ethnic and societal differentials in STI , 2002, Sexually transmitted infections.

[29]  M. Pawlita,et al.  A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. , 2001, Journal of immunological methods.

[30]  J. McGregor,et al.  Human papillomavirus infection and non‐melanoma skin cancer in immunosuppressed and immunocompetent individuals , 2000, Journal of medical virology.

[31]  B. Hansson,et al.  Mucosal human papillomavirus types in squamous cell carcinomas of the uterine cervix and subsequently on fingers , 2000, The British journal of dermatology.

[32]  J. Dillner.  The serological response to papillomaviruses. , 1999, Seminars in cancer biology.

[33]  K. Mullis,et al.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. , 1985, Science.